14th Course: Advances in Urological Oncology
“Prostate Cancer: from Molecular and Cellular Biology to Therapeutic Advancement”

The purpose of the Course is to provide state of the art knowledge and future perspectives on basic and translational research, pathology and advanced therapeutic strategies of prostate cancer in a multidisciplinary approach. Scientific sessions will include interactive discussions between the faculty and the participants. International experts in research and clinical management of prostate cancer will share their views and experience with the audience. The Course is the fourth of a series of courses held under the aegis of the Italian Society of Urological Oncology.

Scientific Preliminary Programme


General Information

• Person wishing to attend the Course should write, within December 20th 2012 to: Prof. Michele Pavone-Macaluso c/o E.D.I.P.O. s.r.l.
  Via Libertà, 103 - Palermo - fax +39 091 6254719 - michpav@tin.it - edi.po@tiscali.it, specifying: • date and place of birth, together with present nationality • degree and other academic qualifications • present position and place of work, address and e-mail.

• Accreditation for Continuing Medical Education (by the Italian Ministry of Health (ECM: Educazione Continua in Medicina) will be applied.

• The registration fee for participants € 2.200,00 plus VAT, to be paid within February 20th, 2013 to the Organising Secretariat – is inclusive of: scientific session, transfer from airport (Palermo or Trapani) to Erice and viceversa, lodging on full board basis and social events.

• Payment by bank draft (bank fees at your charge) Bank: Unicredit, Ag. 7 - Palermo IBAN: IT 66 X 02008 04696 000300353901 Swift Code (BIC): UNCRITM1153 Beneficiary: E.D.I.P.O. s.r.l Via Libertà, 103 – 90143 Palermo.

EMFSC PRESIDENT AND DIRECTOR OF THE CENTRE
Antonino Zichichi

DIRECTOR OF THE SCHOOL
Michele Pavone-Macaluso

DIRECTORS OF THE COURSE
Giario Natale Conti
Como, Italy
Gigliola Sica
Roma, Italy

SCIENTIFIC SECRETARIAT
Alessandro Bertacchini – Bologna, Italy
Enrico Bolito – Orbassano (TO), Italy
Sergio Bracarda – Arezzo, Italy
Fortunata Iacopino – Roma, Italy
Giovanni Luigi Pappagallo – Mirano (VE) – Italy
Carlo Pavone – Palermo, Italy
Vittorio Vavassori – Bergamo, Italy

ORGANISING SECRETARIAT
E.D.I.P.O. s.r.l. Serenella La Cava
Via Libertà, 103 - 90143 - Palermo (Italy)
Tel/Fax: +39.091.6251719
e-mail: edi.po@tiscali.it slacavera@libero.it

Erice, Sicily - Italy April 16-21, 2013
**Instructions to Authors 2013**

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication (print and online) of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing or Editor Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

**Tables.** Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2013 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
A Selection of Recent Papers

Metastatic Biomarker Discovery Through Proteomics. L.T. BRINTON, T.A. BRENTNALL, J.A. SMITH, K.A. KELLY (Charlottesville, VA; Seattle, WA, USA)


Review: Breast Cancer and Metastasis: On the Way Toward Individualized Therapy. A.P. TRAPÊ, A.M. GONZALEZ-ANGULO (Houston, TX, USA)

In Silico Functional Profiling of Individual Prostate Cancer Tumors: Many Genes, Few Functions. I.P. GORLOV, J. BYUN, C.J. LOGOTHETIS (Houston, TX, USA)

Expression of Signal-induced Proliferation-associated Gene 1 (SIPA1), a RapGTPase-activating Protein, Is Increased in Colorectal Cancer and Has Diverse Effects on Functions of Colorectal Cancer Cells. K. JI, L. YE, A.-M. TOMS, R. HARGEST, T.A. MARTIN, F. RUJE, J. JI, W.G. JIANG (Cardiff, UK; Beijing, PR China)

Single Nucleotide Polymorphisms of Genes for EGF, TGF-β and TNF-α in Patients with Pancreatic Carcinoma. L. ZHANG, G. WU, F. HERRLE, M. NIEDERGETHMANN, M. KEESE (Frankfurt; Heidelberg, Germany; Xiamen, P.R. China)

Diagnostic MicroRNA Markers to Screen for Sporadic Human Colon Cancer in Blood. F.E. AHMED, N.C. AMED, P.W. VOS, C. BONNERUP, J.N. ATKINS, M. CASEY, G.J. NUVO, W. NAZIRI, J.E. WILEY, R.R. ALLISON (Greenville, Goldsboro, NC; Columbus, OH, USA)

MGMT Hypermethylation and MDR System in Glioblastoma Cancer Stem Cells. V. CALDERA, M. MELLAI, L. ANNOVAZZI, O. MONZEGLIO, A. PIAZZI, D. SCHIFFER (Pavia; Novara, Italy)

20-HETE-producing Enzymes Are Up-regulated in Human Cancers. A. ALEXANIAN, B. MILLER, R.J. ROMAN, A. SOROKIN (Milwaukee, WI; Jackson, MS, USA)

Unifying the Genomics-based Classes of Cancer Fusion Gene Partners: Large Cancer Fusion Genes are Evolutionarily Conserved. L.M. PAVA, D.T. MORTON, R. CHEN, G. BLANCK (Tampa, FL, USA)
**General Policy**

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

**Editorial Office**

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

**Selection of Recent Articles**

Proteomic Profiling to Identify Prognostic Biomarkers in Heart Failure. P.A. SCOTT, B. ZEIDAN, L.L. NG, M. ZEB, J.A. ROSENGARTEN, S. GARBIS, N.P. CURZEN, J.M. MORGAN, P.A. TOWNSEND (Southampton; Leicester, UK; Athens, Greece)

Diverging *In Vitro* Antibody Isotype Switching Preference in B-Lymphocytes from C57BL/6 and FVB Mice. A.G. PUTHIYAVEETIL, B. OKYERE, C.M. REILLY, D. CAUDELL (Blacksburg, VA, USA)

The Zebrafish - Danio rerio – Is a Useful Model for Measuring the Effects of Small-molecule Mitigators of Late Effects of Ionizing Irradiation. M.W. EPPERLY, N. BAHARY, M. QUADER, V. DEWALD, J.S. GREENBERGER (Pittsburgh, PA, USA)

Breast Cancer: Mechanisms Involved in Action of Phytoestrogens and Epigenetic Changes. A. DAGDEMIR, J. DURIF, M. NGOLLO, Y.-J. BIGNON, D. BERNARD-GALLON (Clermont-Ferrand, France)

Positron-emission Tomography (PET) Imaging Agents for Diagnosis of Human Prostate Cancer: Agonist vs. Antagonist Ligands. P.K. NANDA, B.E. WIENHOFF, T.L. ROLD, G.L. SIECKMAN, J.S. GREENBERGER (Columbia; St. Louis, MO, USA)

In Vivo Models for Defining Molecular Subtypes of the Primitive Neuroectodermal Tumor Genome: Current Challenges and Solutions. J.D. LARSON, D.A. LARGAESPADA (Minneapolis, MN, USA)

Effects of Minocycline on Hematopoietic Recovery After Whole-body Irradiation. S. MEHROTRA, M.J. PECAUT, D.S. GRIDLEY (Loma Linda, CA, USA)

Sequential Changes in the Expression of Wnt- and Notch-related Genes in the Vagina and Uterus of Ovariectomized Mice after Estrogen Exposure. T. NAKAMURA, S. MIYAGAWA, Y. KATSU, T. SATO, T. IGUCHI, Y. OHTA (Yamagata; Okazaki; Sapporo; Yokohama; Tottori, Japan)

Catecholamines Reduce Dose-dependent Oedema Formation and Inflammatory Reaction in an Isolated Rat Lung Model. C. DACHO, A. DACHO, A. GEISSLER, C. HAUSER, K. NOWAK, G. BECK (Heidelberg; Essen; Wiesbaden, Germany)


The Effect of Insulin-like Growth Factor II in the Regulation of Tumour Cell Growth *In Vitro* and Tumourigenesis *In Vivo*. M. HALJÉ, M. NORDIN, D. BERGMAN, W. ENGBRØM (Uppsala, Sweden)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**


Glucose and Lipid Metabolism in Patients with Advanced Pancreatic Cancer Receiving Palliative Chemotherapy. K. ZEISSL, K.G. PARHOVER, V. HEINEMANN, M. HAAS, R.P. LAUBENDER, S. HOLDENRIEDER, C. SCHULZ, S. BOECK (Munich, Germany)............................................................................................. 287

The Prognostic Significance of LIAISON® CA15-3 Assay in Primary Breast Cancer. B. NISMAN, O. MAIMON, T. ALLWEIS, L. KADOURI, T. MALY, T. HAMBURGER, T. PERETZ (Jerusalem, Israel) .... 293

Granocyte-colony Stimulating Factor (G-CSF) Has Significant Efficacy as Secondary Prophylaxis of Chemotherapy-induced Neutropenia in Patients with Solid Tumors: Results of a Prospective Study. G. FREYER, N. JOVENIN, G. YAZBEK, C. VILLANUEVA, A. HUSSAIN, A. BERTHUNE, M. ROTARSKI, H. SIMON, V. BOULANGER, M. HUMMELSBERGER, C. FALANDRY (Lyon; Reims; Besançon; Quimper; Saint Cloud; Bayonne; Brest; Carcassonne; Béziers, France) ................................................................... 301

Lack of Association of Proteinuria and Clinical Outcome in Patients Treated with Bevacizumab for Metastatic Colorectal Cancer. S. IWASA, T.E. NAKAJIMA, K. NAGASHIMA, Y. HONMA, K. KATO, T. HAMAGUCHI, Y. YAMADA, Y. SHIMADA (Tokyo; Kanagawa; Saitama, Japan) ............................................................ 309

Long-term Results of Brachytherapy in Early Mobile Tongue Cancer with 10-Year Minimal Follow-up. M.M. ABDALMEAR, M. TOMITA, H. SHIBUYA (Tokyo, Japan)................................................................. 317

Long-term Follow-up after Preoperative Chemotherapy Using Pemetrexed (Alimta) in Rectal Cancer. T. SWARTLING, K. KODEDA, B. GUSTAVSSON, K. DERWINGER (Gothenburg, Sweden) ............................................. 325

Utility of Mesothelin, L1CAM and Afamin as Biomarkers in Primary Ovarian Cancer. B. AKTAS, S. KASIMIR-BAUER, P. WIMBERGER, R. KIMMIG, M. HEUBNER (Essen, Germany)................................. 329

Second Primary Cancer in Patients with Papillary Thyroid Carcinoma. C. ZAFON, G. OBIOLS, J. MESA (Barcelona, Spain) ............................................................................................................ 337

Association of pre-miR-146a rs2910164 Polymorphism with the Risk of Head and Neck Cancer. Z. ORSÓS, I. SZANYI, A. CSEJTEI, I. GERLINGER, I. EMBER, I. KISS (Pécs; Szombathely, Hungary) ............ 341

Reviews (pages 1, 13, 21, 29, 39)

Induction of Death of Leukemia Cells by TW-74, A Novel Derivative of Chloro-naphthoquinone. M. HALLAK, B.K. THAKUR, T. WINN, O. SHPILBERG, S. BITTNER, Y. GRANOT, I. LEVY, I. NATHAN *(Beer Sheva; Petah Tikva, Israel; Hannover, Germany; Kyaukse, Myanmar) ................................................ 183

Study of Genetic and Epigenetic Alterations in Urine Samples as Diagnostic Markers for Prostate Cancer. E. DIMITRIADIS, T. KALOGEROPoulos, S. VELAETI, S. SOTIRIOU, E. VASSILOU, L. FASOULIS, V. KLAPSAS, M. SYNESIOU, A. APOSTOLAKI, T. TRANGAS, N. PANDIS *(Athens; Ioannina; Chios, Greece) ............................................................................................................................... ........ 191

Expression Profile of Receptor Activator of Nuclear-κB (RANK), RANK Ligand (RANKL) and Osteoprotegerin (OPG) in Breast Cancer. S. OWEN, L. YE, A.J. SANDERS, M.D. MASON, W.G. JIANG *(Cardiff, UK) ........ 199

HAVcR-1 Expression in Human Colorectal Cancer and its Effects on Colorectal Cancer Cells In Vitro. Y. WANG, T.A. MARTIN, W.G. JIANG *(Cardiff, UK; Beijing, China) ........................................................ 207


Role of Pesticides in the Induction of Tumor Angiogenesis. S.P. BHARATHI, H.M. RAJ, S. JAIN, B.D BANERJEE, T. AHMED, V.K. ARORA *(Mysore, Karnataka; New Delhi, India) .................. 231

**Clinical Studies**

Treatment of Vaginal Recurrences in Endometrial Carcinoma by High-dose-rate Brachytherapy. B. SORBE, K. SÖDERSTRÖM *(Örebro; Umeå, Sweden) .......................................................... 241

Interstitial HDR Brachytherapy for Advanced Recurrent Squamous Cell Carcinoma of the Head and Neck. S. WIEGAND, A.M. SESTERHENN, A.P. ZIMMERMANN, G. STRASSMANN, T. WILHELM, J.A. WERNER *(Marburg; Borna, Germany) ........................................... 249

CEA Fluctuation During a Single Fluorouracil-based Chemotherapy Cycle for Metastatic Colorectal Cancer. K. HERMUNEN, C. HAGLUND, P. OSTERLUND *(Helsinki, Finland) .......................................................... 253


Extensive Distal Pancreatectomy for Pancreatic Tumor. M. NAKAMURA, T. OHTSUKA, H. NAKASHIMA, Y. NAGAYOSHI, H. KONO, K. TSUTSUMI, S. TAKAHATA, M. TANAKA *(Kurashiki; Fukuoka, Japan) ........ 267


*Contents continued on the preceding page*
Anticancer Activity of β-Elemene and its Synthetic Analogs in Human Malignant Brain Tumor Cells. Q.Q. LI, R.X. LEE, H. LIANG, Y. ZHONG (Guangxi, PR China; Morgantown, WV; Bethesda, MD, USA) .......................... 65


Primer Dosing of S. typhimurium A1-R Potentiates Tumor-Targeting and Efficacy in Immunocompetent Mice. Y. TOME, Y. ZHANG, M. MOMEMIYAMA, H. MAEHARA, F. KANAYA, K. TOMITA, H. TSUCHIYA, M. BOUVET, R.M. HOFFMAN, M. ZHAO (San Diego, CA, USA; Okinawa; Kanazawa, Japan) ................... 97

Subcellular Real-Time Imaging of the Efficacy of Temozolomide on Cancer Cells in the Brain of Live Mice. M. MOMEMIYAMA, A. SUETSUGU, T. CHISHIMA, M. BOUVET, I. ENDO, R.M. HOFFMAN (San Diego, CA, USA; Yokohama, Japan) ................................................................................................................ 103

Enhanced Resection of Orthotopic Red-fluorescent Protein-expressing Human Glioma by Fluorescence-guided Surgery in Nude Mice. M. MOMEMIYAMA, Y. HIROSHIMA, A. SUETSUGU, Y. TOME, S. MII, S. YANO, M. BOUVET, T. CHISHIMA, I. ENDO, R.M. HOFFMAN (San Diego, CA, USA; Yokohama, Japan) ................................................................................................................ 107

PPP2R1A Mutation Is a Rare Event in Ovarian Carcinoma Across Histological Subtypes. M. RAHMAN, K. NAKAYAMA, M.T. RAHMAN, N. NAKAYAMA, H. KATAGIRI, A. KATAGIRI, T. ISHIBASHI, M. ISHIKAWA, K. IDA, Y. OTSUKI, S. NAKAYAMA, K. MIYAZAKI (Izumo; Hamamatsu, Japan) ............................................ 113

Immunohistochemical Expression of PTTG in Brain Tumors. F. SALEHI, B.W. SCHEITHAUER, S. SHARMA, K. KOVACS, R.V. LLOYD, M.D. CUSIMANO, D.G. MUNOZ (Toronto, ON, Canada; Rochester, MN, USA) ................................................................. 119

Effects of Transferrin Conjugates of Artemisinin and Artemisinin Dimer on Breast Cancer Cell Lines. Y. GONG, B.M. GALLIS, D.R. GOODLETT, Y. YANG, H. LU, E. LACOSTE, H. LAI, T. SASAKI (Seattle, WA) ......................................................... 123

Interaction between Gambogic Acid and Dihydrofolate Reductase and Synergistic Lethal Effects with Methotrexate on Hepatoma Cells. J. DESCHATRETTE, K. NG-BONAVENTURE, L. PHILIPPE, C. WOLFROUM (Orsay; Châtenay-Malabry, France) ......................................................... 133

The Nanoparticulate Quillaja Saponin BBE Is Selectively Active Towards Renal Cell Carcinoma. S.B. HASSAN, J. GULLBO, K. HU, S. BERENJIAN, B. MOREIN, P. NYGREN (Uppsala, Sweden) ................................................................. 143

Proteomic Analysis Showed Down-regulation of Nucleophosmin in Progressive Tumor Cells Compared to Regressive Tumor Cells. T. TAKEAWA, Y. KURAMITSU, Y. WANG, F. OKADA, K. TOKUDA, T. KITAGAWA, Y. UEYAMA, K. NAKAMURA (Yamaguchi; Yonago, Japan) ........................................... 153

Intratumoural Interleukin-2 Therapy Can Induce Regression of Non-resectable Mastocytoma in Dogs. P.G.P.M. ZIEKMAN, W. DEN OTTER, J.F.V. TAN, E. TESKE, J. KIRKENSTEIJN, J.-W. KOTEN, J.J.L. JACOBS (Amsterdam; Oisterwijk; Gouda; Utrecht, Netherlands) ......................................................... 161


Contents continued on the preceding page